A team at IOCB Prague revealed a novel phase where liquids flip rapidly between metal and nonmetal states. The theory, based on advanced modeling, was featured in Nature Communications.

The scientific team of Dr. Pavel Majer from the IOCB of the CAS has developed a new substance with the potential to treat the autoimmune disease alopecia areata, which is manifested by hair loss.

Roman and Anton Bushuiev joined experts from 14 institutes in MassSpecGym, a project to benchmark AI methods for discovering natural molecules from MS, aiding drug development, ecology, and space research.

A new building has gone up on the IOCB campus that will serve as headquarters for the cryogenic electron microscopy laboratory of Dr. Tomáš Kouba.

Dr. Tomáš Pluskal has been accepted into the prestigious ‘Young Investigator Programme’ of the EMBO and has also secured the ERC grant.

Scientists from IOCB Prague have created compounds a million times more stable than those used to treat tumors or as contrast agents for magnetic resonance imaging.

An important step in countering antibiotic resistance has been made by researchers from IOCB Prague, the Institute of Microbiology and the Institute of Biotechnology of the CAS.

IOCB Prague opened its new branch in Boston, USA on October 18, 2024. The move puts the institute in proximity to scientific institutions, such as Harvard University, MIT, and Boston Medical Center.

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants.

Even heavily modified double helices of DNA are stable enough to be used for special applications.